GlobalData on MSN

BridgeBio’s stock up as muscular dystrophy therapy meets Phase III endpoints

BridgeBio Pharma will seek US approval of its limb-girdle muscular dystrophy (LGMD) small molecule after the drug met its ...

BridgeBio rises after late-stage muscular dystrophy trial success

BridgeBio Pharma shares surge on positive BBP-418 trial results for limb-girdle muscular dystrophy. Read more here.
Fierce Biotech

BridgeBio aces phase 3 rare disease test, clearing path to FDA

The biotech’s phase 3 delivered the hoped-for second biomarker hit, reporting an 82% decline in serum creatine kinase after ...
BMJ

Neutralisation of muscle tumour necrosis factor alpha does not attenuate exercise-induced muscle pain but does improve muscle strength in healthy male volunteers

Brain Function Research Unit, School of Physiology, University of the Witwatersrand, Johannesburg, South Africa L Loram, School of Physiology, University of the Witwatersrand, 7 York Road, Parktown, ...